Live
- India leads world in science, innovation research: Minister
- Flash flood in Indonesia's South Tapanuli claims two lives
- MahaYuti's electoral success testament to leadership of PM Modi, HM Shah: Ajit Pawar
- Unproven remedies: Tata Memorial Hospital slams Sidhu’s viral ‘diet cure’ cancer claim
- People voted in favour of development, rejected negative politics: CM Shinde
- Rajasthan bypolls: CM Bhajan Lal Sharma's governance credited with BJP's impressive show
- Aaditya Thackeray retains Worli defeating Shinde faction nominee Milind Deora
- Over 20 Injured in Multi-Vehicle Collision on Mangaluru-Bengaluru Highway
- South Korea not to attend Sado memorial amid controversy over Japan's pick for government representative
- Five major factors that helped MahaYuti to win landslide victory
Pharma giant Pfizer to absorb Mylan
Pfizer, the country's largest drugmaker, will absorb the generic pharmaceutical company Mylan, potentially creating a global generic powerhouse.
New York: Pfizer, the country's largest drugmaker, will absorb the generic pharmaceutical company Mylan, potentially creating a global generic powerhouse.
The two companies said on Monday that they'll combine Mylan, a $10 billion company, with Pfizer's Upjohn, which sells household names from Viagra to cholesterol fighter Lipitor that have lost patent protection.
The deal, expected to close in the middle of next year, will have estimated annual revenue in excess of $19 billion with sales in more than 165 countries.
The name for the new company has yet to be determined. The two companies have worked together closely for years. Pfizer manufactures Mylan's EpiPen, an auto-injector used to halt life-threatening allergic reactions.
Mylan was heavily criticized, and its CEO Heather Bresch was brought before Congress two years ago, to answer questions about the price of the EpiPen, which had jumped five-fold to $600 for two doses.
EpiPens have been in short supply for more than a year because of quality problems and upgrades at a Pfizer factory.
Upjohn, the name of one of the companies Pfizer gobbled up during a spate of acquisitions in the 1990s and 2000s, sells off-patent and generic drugs that include the stars that drove Pfizer's growth: pain killers Celebrex and Lyrica, Norvasc for high blood pressure, Effexor for more heartburn and psychiatric drugs Xanax and Zoloft.
